Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASCHIX:GMABC 97 3-Year EBITDA Growth Rate is 6.50% as of Jun. 2026, which is 80% below its 10-year median of 33.20. GuruFocus rates CHIX:GMABC with a GF Score™ of 97/100 and a GF Value™ of kr2,150.74 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,127 Biotechnology companies, Genmab AS ranks worse than 60.78% on this metric.
During the past 12 months, Genmab AS's average EBITDA Per Share Growth Rate was -20.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 6.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 29.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Genmab AS was 129.80% per year. The lowest was -7.70% per year. And the median was 33.20% per year.
Genmab AS (CHIX:GMABc) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Genmab AS 3-Year EBITDA Growth Rate Related Terms
CHIX:GMABC vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Genmab AS's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Genmab AS's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 6.50% mean?
Genmab AS (CHIX:GMABC) has a 3-Year EBITDA Growth Rate of 6.50% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Genmab AS and its competitors. This is 80% below median its historical median of 33.20. According to the industry distribution chart, Genmab AS ranks #685 out of 1127 companies in the Biotechnology industry, placing it in the top 60.8%.
Is Genmab AS's 3-Year EBITDA Growth Rate too high?
Genmab AS's current 3-Year EBITDA Growth Rate of 6.50% is 80% below median its 10-year median of 33.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.90. Genmab AS's value of 6.50% is 56.4% below this industry median. Based on the distribution chart, Genmab AS ranks #685 out of 1127 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #685 out of 1127 companies for 3-Year EBITDA Growth Rate. This places Genmab AS in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. Genmab AS's value of 6.50% is 56.4% below this benchmark. While the company's 10-year median is 33.20 vs. the industry median of 14.90, Genmab AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genmab AS's current 3-Year EBITDA Growth Rate of 6.50% is 56.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Genmab AS and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genmab AS's current 3-Year EBITDA Growth Rate is 6.50%, which is 80% below median its own 10-year median of 33.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,150.74, compared to a current price of kr2,163.00 — trading 0.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 6.50%, which is 80% below median its 10-year median of 33.20 and 56.4% below the Biotechnology industry median of 14.90. Genmab AS's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current 3-Year EBITDA Growth Rate is 6.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be overvalued.
The current stock price of kr2,163.00 is trading 0.6% above its estimated GF Value™ of kr2,150.74.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for CHIX:GMABC:
3-Year EBITDA Growth Rate: 6.50% (80% below median its 10-year median of 33.20)
GF Value™: kr2,150.74 vs. price of kr2,163.00 (0.6% above fair value)
Industry Position: 56.4% below the Biotechnology median (#685 of 1127)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score
Get the complete analysis for CHIX:GMABC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
